- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01736319
Artemisinin-resistant Malaria in Cambodia
Artemisinin-resistant Plasmodium Falciparum Malaria in Cambodia
Background:
- Artemisinin-based combination therapies (ACTs) are the first-line treatments for malaria. ACTs are highly effective, but malaria caused by the Plasmodium falciparum parasite is becoming resistant to some ACTs. ACT-resistant malaria has shown up in some parts of Cambodia, but not yet in other parts of the country. This has been shown by treating patients with ACTs, checking the amount of parasites in the patient s blood every 6 hours, and calculating the rate of parasite clearance. The parasite clearance rate in response to ACTs is getting slower in western Cambodia and may be the first sign of ACT resistance. Researchers want to study how effective ACTs are in different regions of Cambodia. This study will look at the extent of ACT resistance and how widespread ACT-resistant malaria has become.
Objectives:
- To compare the prevalence of ACT-resistant malaria in western, northern and eastern Cambodia.
Eligibility:
- Individuals between 2 and 65 years of age who have uncomplicated Plasmodium falciparum malaria and have not taken any antimalarial drugs for their symptoms in the previous 7 days.
Design:
- Participants will be recruited from clinics and hospitals in three Cambodian provinces.
- Participants will be informed about the study and their consent to participate in the study will be obtained.
- A venous blood sample will be obtained from patients before treatment and used for laboratory experiments to measure parasite and patient factors that might affect the parasite clearance rate.
- Participants with malaria will be treated with dihydroartemisinin-piperaquine (DHA-PPQ), the standard first-line treatment for malaria in Cambodia.
- Treatment will be monitored with frequent blood samples obtained from a finger prick. The amount of malaria parasites in each blood sample will be counted and followed until they are no longer detectable.
- Participants will have weekly follow-up visits for up to 9 weeks. Finger-prick blood samples will be taken at each visit to see if the parasites reappear after treatment with ACT.
연구 개요
상태
상세 설명
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Phnom Penh, 캄보디아
- National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
INCLUSION CRITERIA (Parasite Recrudescence Study):
- Age 2 to 65 years, inclusive
- Uncomplicated P. falciparum malaria
- Temperature greater than or equal to 37.5 degrees Celsius or history of fever within the last 24 h
- P. falciparum asexual parasite density less than or equal to 200,000/microL
- Willingness to allow the storage of blood samples collected as part of the study
- Willingness and ability of patients/guardians to comply with the protocol for the duration of the study.
EXCLUSION CRITERIA (Parasite Recrudescence Study):
- Severe malaria: diminished consciousness, respiratory distress, severe prostration, anuria, jaundice, hemoglobinuria, repetitive vomiting, or cessation of eating and drinking
- Non-malaria etiology of febrile illness (e.g., respiratory tract infection) evident by history and physical examination
- Hematocrit <25%
- Treatment of present symptoms with an antimalarial drug within the previous 7 days
- Pregnancy or breastfeeding
- History of allergy or known contraindication to artemisinins or MQ
- Splenectomy
- P. vivax parasitemia
INCLUSION CRITERIA (Peripheral Blood Collection Study):
- Healthy-appearing adults greater than or equal to 18 years old
- Residence in Pursat province
- Willingness to participate in the study as evidenced by informed consent
EXCLUSION CRITERIA (Peripheral Blood Collection Study):
- Pregnancy
- Hematocrit <25%
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859. Erratum In: N Engl J Med. 2009 Oct 22;361(17):1714.
- Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012 May 26;379(9830):1960-6. doi: 10.1016/S0140-6736(12)60484-X. Epub 2012 Apr 5.
- Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B, Anderson JM, Duong S, Chuor CM, Taylor WR, Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013 Dec;13(12):1043-9. doi: 10.1016/S1473-3099(13)70252-4. Epub 2013 Sep 11.
- White NJ. The parasite clearance curve. Malar J. 2011 Sep 22;10:278. doi: 10.1186/1475-2875-10-278.
- Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, Blessborn D, Song L, Tullo GS, Fay MP, Anderson JM, Tarning J, Fairhurst RM. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016 Mar;16(3):357-65. doi: 10.1016/S1473-3099(15)00487-9. Epub 2016 Jan 8.
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 완료
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 999912163
- 12-I-N163
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Plasmodium Falciparum 말라리아에 대한 임상 시험
-
Medicines for Malaria Venture완전한복잡하지 않은 Plasmodium Falciparum 말라리아우간다, 베냉, 부키 나 파소, 콩고 민주 공화국, 가봉, 모잠비크, 베트남
-
Karolinska University HospitalMuhimbili University of Health and Allied Sciences완전한
-
David SaundersNational Centre for Parasitology, Entomology and Malaria Control, Cambodia; Royal Cambodian... 그리고 다른 협력자들정지된
-
Jomaa Pharma GmbHCentre de Recherche Médicale de Lambaréné알려지지 않은단순 급성 Plasmodium Falciparum 말라리아의 경구 치료
-
Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.PATH; World Health Organization; Xinhua Hospital, Shanghai Jiao Tong University School of... 그리고 다른 협력자들완전한
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical Research...완전한
-
Novartis PharmaceuticalsMedicines for Malaria Venture완전한급성 복잡하지 않은 Plasmodium Falciparum 말라리아태국, 가봉, 말리, 우간다, 부키 나 파소, 인도, 케냐, 모잠비크, 베트남
-
Novartis Pharmaceuticals모병복잡하지 않은 Plasmodium Falciparum 말라리아부키 나 파소, 가봉, 코트디부아르, 케냐, 가나, 우간다
-
University of Oxford모병복잡하지 않은 Plasmodium Falciparum 말라리아르완다
-
Medicines for Malaria VentureShin Poong Pharmaceuticals; Institute of Tropical Medicine, University of Tuebingen완전한